| INCY Technical Analysis Data | ||||||||||||||||
Also see: |
55.71| INCY Current Stock Quote |
 Free INCY Email Alerts:
Get Dividend Alerts 
Get SEC Filing Alerts
|
| INCY Stock Price Chart |
| INCY Technical Analysis Charts |
  |
| About Incyte Corporation |
| Incyte is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. JAKAFI (ruxolitinib) is Co.'s initial product approved by the U.S. Food and Drug Administration for the treatment of adults with intermediate or high-risk myelofibrosis, for the treatment of adults with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea, for the treatment of steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients 12 years and older and for the treatment of chronic GVHD after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older. When researching a stock like Incyte, many investors are the most familiar with Fundamental Analysis — looking at a company's balance sheet, earnings, revenues, and what's happening in that company's underlying business. Investors who use Fundamental Analysis to identify good stocks to buy or sell can also benefit from INCY Technical Analysis to help find a good entry or exit point. Technical Analysis is blind to the fundamentals and looks only at the trading data for INCY stock — the real life supply and demand for the stock over time — and examines that data in different ways. |
| INCY Technical Analysis Charts |
  |
| Video: Technical Analysis | |
|
Video: Technical Analysis
| INCY Technical Analysis Peers |
| Incyte (INCY) is categorized under the Healthcare sector; to help you further research Technical Analysis, below are some other companies in the same sector:
IQV Technical Analysis |